Digital Therapeutics

An interdisciplinary gathering at the 2025 virtual conference of the Society for Digital Mental Health heard presentations and panel discussions on digital therapeutics, along with reports of studies on the technology and outcomes by student and young researchers.

Innovative digital therapeutics like CT-155 are transforming mental health treatment, targeting negative symptoms of schizophrenia and enhancing depression care. Check out this conversation with Shaheen Lakhan, MD, PhD.

US Senators have reintroduced The Access to Prescription Digital Therapeutics Act to increase access to prescription digital therapeutics and decrease barriers to care.

Through cinematherapy, Ted Perkins created a program centered on addiction in film that is now used in recovery centers and clinics across the US and Canada.

How one resident found a free and accessible way to cope with her arachnophobia.

Psychiatry: one of the most dynamic and rapidly evolving specialties in medicine.

Here are 4 means of coping with the diagnostic uncertainty of bipolar mixed states.

How can we improve rural mental health?

DaylightRx becomes the very first FDA-cleared digital treatment for generalized anxiety disorder.

Here are highlights from the week in Psychiatric Times.

The CDC suggests that disrupted access to ADHD medications may increase risk of overdose and injury.

An expert discusses the potential of smartphones as treatment measurement tools at the 2024 ASCP Annual Meeting.

How does artificial intelligence have the potential to shape the future of psychiatry?

How can novel technologies help address stigma and improve care for patients with SUDs?

Here are some updates from the world of psychiatry throughout the month of April.

What is new in research on opioid use disorder?

Tris Pharma has formed the organization along with a licensing agreement with Braingaze for development, distribution of the technology.

How can telehealth aid in the treatment of opioid use disorders in this patient population?

From a look at record-high suicide rates to subspecialty shortages in psychiatry, here are highlights from the week in Psychiatric Times.

From a groundbreaking FDA approval to the hidden toll of COVID-19, here are highlights from the week in Psychiatric Times.

The FDA has cleared the first prescription digital therapeutic for major depressive disorder, Rejoyn.

The experts weighed in on a wide variety of psychiatric issues for the March 2024 issue of Psychiatric Times.

Here's how a good online reputation can help clinicians provide a positive patient experience.

Here’s a look back at selections from our February content series on eating disorders.